Good Day BIO Newsletter

Happy March. We recap yesterday’s Rare Disease Day hearing—and the bipartisan support for a few key BIO priorities—and look at a few things you might have missed at the BIO CEO and Investor Conference. (552 words, 2 minutes, 45 seconds)

A leap year means we have an extra day in the month to talk about rare disease patients and R&D. Plus, Agriculture Secretary Tom Vilsack talked about biotech on the Hill and BIO’s David Thomas writes about the vaccine pipeline in International Business Times. (849 words, 4 minutes, 19 seconds)

BIO members and CEOs sent a letter to congressional leaders urging them to pass the ORPHAN Cures Act and support rare disease R&D. Plus, more highlights from the BIO CEO and Investor Conference, including what executives are saying about the policy outlook and AI. (676 words, 3 minutes, 22 seconds)

On Day 1 of the BIO CEO and Investor Conference, CEOs and experts explained why it’s a great time to invest in innovations such as gene therapy and vaccines. Meanwhile, the I am BIO Podcast launches its new season with a look at the first approved CRISPR-based gene therapy and its impact on sickle cell patients. (780 words, 3 minutes, 54 seconds)

It’s a big week—with the BIO CEO and Investor Conference kicking off in New York, Rare Disease Week happening in D.C., and the World Trade Organization (WTO) Ministerial in Abu Dhabi. Here’s what we’re watching—follow along all week! (785 words, 3 minutes, 55 seconds)

BIO’s soon-to-be CEO John F. Crowley talks biomarkers and rare disease regulatory pathways, and U.S. Rep. Brett Guthrie explains the impact of policies to control drug prices. (557 words, 2 minutes, 47 seconds)

Bipartisan lawmakers weigh in on NIST’s proposal to use Bayh-Dole to control drug prices, and USDA research highlights the impact of biotech on farm productivity. (487 words, 2 minutes, 26 seconds)

Today, we look at how BIO members are advancing cell therapies and a One Health program that’s reducing mosquito-borne disease. (479 words, 2 minutes, 23 seconds)  P.S. BIO Vice Chair (and incoming CEO) John F. Crowley will speak today, Feb. 21, at the Reagan-Udall Foundation for the FDA workshop about qualifying biomarkers to support rare disease regulatory pathways—click here to register to watch online.

A BIO Board member explains how the ORPHAN Cures Act can save rare disease drug development, and the world’s first GMO banana approved for human consumption could thwart a future “banana pandemic.” (619 words, 3 minutes, 5 seconds)

Wrapping up a busy week before the long weekend, with coverage of yesterday’s hearing on vaccine safety systems, a bill to reauthorize the Rare Pediatric Disease Priority Review Voucher Program, and what Agriculture Secretary Tom Vilsack said yesterday about climate tech for farmers. (691 words, 3 minutes, 27 seconds)  We’re taking a break on Monday, February 19, for President’s Day. We will return on Tuesday, February 20.